Clinical Trials
52 trialsIMG-7289-CTP-203
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Thomas Jefferson University
Ruxolitinib Phosphate and Azacytidine in Treating Patients With Myelofibrosis or Myelodysplastic Syndrome/Myeloproliferative Neoplasm
M.D. Anderson Cancer Center
Dasatinib as Therapy for Myeloproliferative Disorders (MPDs)
M.D. Anderson Cancer Center
Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies
Thomas Jefferson University
Efficacy and Safety of P1101 in Polycythemia Vera Patients for Whom the Standard of Treatment is Difficult to Apply
PharmaEssentia Japan K.K.
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)
Incyte Corporation
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Protagonist Therapeutics, Inc.
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
M.D. Anderson Cancer Center
Pegasys® in Patients With Myeloproliferative Diseases
M.D. Anderson Cancer Center
Low-PV
FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETS
AIRPORT-MPN
Ottawa Hospital Research Institute
PACIFIC
Protagonist Therapeutics, Inc.
Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia
Sierra Oncology LLC - a GSK company
LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis
M.D. Anderson Cancer Center
Shorter Course Tacro After NMA, Related Donor PBSCT With High-dose Posttransplant Cy for Hard-to-Engraft Malignancies
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
A Phase 2 Study of RO7490677 In Participants With Myelofibrosis
Hoffmann-La Roche
GITMO-MF2010
Gruppo Italiano Trapianto di Midollo Osseo
PD-1 Inhibition in Advanced Myeloproliferative Neoplasms
Icahn School of Medicine at Mount Sinai
Bone Marrow Transplant in Treating Patients With Hematologic Cancers
H. Lee Moffitt Cancer Center and Research Institute
Fludarabine Phosphate and Total Body Irradiation Followed by a Donor Peripheral Stem Cell Transplant in Treating Patients With Myelodysplastic Syndromes or Myeloproliferative Disorders
Fred Hutchinson Cancer Center
Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer
Fred Hutchinson Cancer Center
Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases
Italfarmaco
PV
Italfarmaco
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Roswell Park Cancer Institute
Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)
M.D. Anderson Cancer Center
Pomalidomide for Myelofibrosis Patients
M.D. Anderson Cancer Center
Allogeneic Stem Cell Transplantation for Myelofibrosis and Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation
Swiss Cancer Institute
A Study of Anagrelide Controlled Release (GALE-401) in Patients With High Platelet Counts Due to Bone Marrow Disorders
Galena Biopharma, Inc.
Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)
Icahn School of Medicine at Mount Sinai
T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies
University of Chicago
Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms
Hospital Israelita Albert Einstein
ET/PV
Geron Corporation
Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera
PV-Nord
Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis
Teva Branded Pharmaceutical Products R&D, Inc.
Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia
National Cancer Institute (NCI)
Effects of Imatinib Mesylate in Polycythemia Vera
Niguarda Hospital
Lenalidomide and Prednisone in Treating Patients With Myelofibrosis
National Cancer Institute (NCI)
Imatinib Mesylate in Treating Patients With Myelofibrosis
National Cancer Institute (NCI)
Tipifarnib in Treating Patients With Myelofibrosis and Myeloid Metaplasia
National Cancer Institute (NCI)
Donor Bone Marrow Transplant in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders
H. Lee Moffitt Cancer Center and Research Institute
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
European Organisation for Research and Treatment of Cancer - EORTC
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
National Institutes of Health Clinical Center (CC)
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
Case Comprehensive Cancer Center
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Hoag Memorial Hospital Presbyterian
Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia
Mayo Clinic
Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Myelofibrosis
Fred Hutchinson Cancer Center
Treatment of Polycythemia Vera With Gleevec
Weill Medical College of Cornell University